Introduction Home > Introduction

  Chongqing Fuan Pharmaceutical (Group) Co., Ltd. was established in February 25, 2004, March 22, 2011 the company successfully listed on the Shenzhen Stock Exchange GEM (Stock Code: 300194).
  The company is located in Chongqing Changshou Economic and Technological Development Zone, covers an area of ??about 100 mu, building area of ??20,000 square meters, registered capital of 133.4 million yuan. The company mainly engaged in the antibiotic bulk drugs and formulations production, sales, the main products of aztreonam, ticarcillin sodium, methyl benzyl amoxicillin sodium, sodium and other characteristics ceftezole varieties of antibiotics. End of 2011, total assets reached 1.817 billion yuan, year 2011 achieved total revenue of 359 million yuan, total profit reached 114 million yuan, net profit of 9,523 million.
  The company owns five wholly owned and controlled subsidiaries, namely: to engage in drug development in Chongqing Fuan Pharmaceutical Group at the State Drug Development Limited is engaged in the production of pharmaceutical intermediates wide NKT Pharmaceutical Co., Ltd., in preparation for the main production Business Chongqing Fuan Pharmaceutical Group Qingyu Tang Pharmaceutical Co., Ltd., Hubei People Pharmaceutical Co., Ltd. and is principally engaged in pharmaceutical sales Biological Products Co., Ltd. in Chongqing. The company has been formed from the drug development to pharmaceutical intermediates, bulk drugs, formulations production, to product sales of a complete industrial chain.
  The company has been the Ministry of Science, Torch High Technology Industry Development Center as high-tech enterprises, the State Torch Plan Key High-tech enterprises, and was identified as the Chongqing Municipal Science and Technology Commission of Chongqing Engineering Research Center of anticancer drugs; company's products for card amoxicillin sodium was named national key new products; Sulbenicillin sodium obtain Chongqing outstanding key new product title; aztreonam powder mixed high-tech products to be included in the plan of Chongqing; nicergoline capsules, etc. 8 products oxiracetam was included in Chongqing key new product plans.
  Group Company employees more than 1,000 people, including Dr 3, 21 master's, bachelor degree or above 129 people, talent echelon and reasonable structure. The company has "dedicated, professional, concentrate on doing drugs to the public well-being of its mission, maximize shareholder" business purpose, adhere to the "people-oriented, technology first, innovation is the soul, the pursuit of excellence" business philosophy, and Sichuan Antibiotic Research Institute, College of Pharmacy, West China Medical University, Chongqing Medical University, Chongqing Pharmaceutical Research Institute, Chongqing Institute of the drugs and other research institutions to establish a cooperative research and development of effective models, and set about establishing a number of research institutions with foreign extensive contacts, global business strategy for the company to build a solid platform.
  Currently, the company in the research project covers the spiritual system classes, cardiovascular, anti-tumor, anti-infective and many other categories, the number of antibacterial drug development company accounted for the proportion of total R & D projects declined. Key species in the study, including capecitabine, hair care triptans, tigecycline and other varieties. Anti-infectious and non-anti-infective number of varieties accounted for the proportion of the total number of products in the research were 47% and 53%, the company registration of new R & D has been trying to antibiotics and specialist drug development collaboration reorientation. "Twelve Five" period, the company will strive to complete the antibiotic products dominated by the antibiotics and medicines to the common development of strategic adjustment, and actively promote the optimization of product structure, accelerate product development and industrialization of scientific research for the company's future development lay a solid foundation.

Contacts: Tian Xiangqin

Tel: 0086 23 61218100

Email: xiangqin.tian@fapharm.com


Contacts: Wu Yu

Tel: 0086 23 61028787

Email: fuanpharm@126.com

Add:No 2,Huang Yang Road,Yu Bei District,Chongqiang,China